Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 6/20 | 0.42 |
| ▸ | REN | P00797 | 9/20 | 0.36 |
| ▸ | CTSC | P53634 | 5/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL294851 | 0.82 | SSTR4 (0.41) | SSTR4RENCTSC | |
| SCHEMBL1194327 | 0.82 | SSTR4 (0.41) | SSTR4RENCTSC | |
| SCHEMBL2688364 | 0.82 | SSTR4 (0.41) | SSTR4RENCTSC | |
| SCHEMBL295081 | 0.82 | SSTR4 (0.44) | SSTR4RENCTSC | |
| SCHEMBL3364696 | 0.82 | SSTR4 (0.41) | SSTR4RENCTSC | |
| SCHEMBL23230712 | 0.82 | SSTR4 (0.44) | SSTR4RENCTSC | |
| SCHEMBL4524846 | 0.82 | CTSC (0.40) | SSTR4RENCTSCKCNH2 | |
| SCHEMBL11244759 | 0.80 | CTSC (0.39) | SSTR4RENCTSCKCNH2 | |
| SCHEMBL294388 | 0.79 | SSTR4 (0.46) | SSTR4RENCTSC | |
| SCHEMBL17559282 | 0.79 | SSTR4 (0.42) | SSTR4REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107624113-B | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2020-10-23 | — | — | CN | claimed |
| EP-3292120-B1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | claimed |
| EP-3292120-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | H. Hoffnabb-La Roche Ag (CH) | 2018-03-14 | — | — | EP | claimed |
| US-9845322-B2 | Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-12-19 | — | — | US | claimed |
| WO-2016177655-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-10 | — | — | WO | claimed |
| US-20160326167-A1 | Novel Tetrahydropyridopyrimidines and Tetrahydropyridopyridines for the Treatment and Prophylaxis of Hepatitis B Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2016-11-10 | — | — | US | claimed |
| EP-4219767-A1 | PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| CN-116196411-A | PAPD5 and PAPD7 inhibitors for the treatment of hepatitis B infection | 豪夫迈·罗氏有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-109328237-B | Inhibitors of PAPD5 and PAPD7 for the treatment of hepatitis b infection | 豪夫迈·罗氏有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-20220096527-A1 | PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-11191775-B2 | PAPD5 and PAPD7 inhibitors for treating a hepatitis B infection | HOFFMANN-LA ROCHE INC. (US) | 2021-12-07 | — | — | US | disclosed |
| CN-107624113-B | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2020-10-23 | — | — | CN | disclosed |
| US-20190194768-A1 | PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2016177655-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-10 | — | — | WO | disclosed |
| US-6210859-B1 | SENSITIVITY, RESOLUTION, HEAT-RESISTANCE AND STABILITY AFTER EXPOSURE, ULTRAFINE PATTERNS CAN BE FORMED IRRESPECTIVE OF ANY SUBSTRATE, LARGER SCOPE OF EXPOSURE CAN BE OBTAINED, A MODIFIEDPOLYHYDROXYSTYRENE COPOLYMER | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2001-04-03 | — | — | US | disclosed |
| US-H1893-H | REACTING A HALOKETONE COMPOUND OR SALT WITH AN OXIDOREDUCTASE ENZYME SUPPLYING MICROORGANISM OR OXIDOREDUCTASE ENZYME CONTAINING MATERIAL OBTAINED FROM THE MICROORGANISM, CATALYZES THE REDUCTION OF HALOKETONE TO FORM HALOHYDROXIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-10-03 | — | — | US | disclosed |
| US-5776933-A | Method of inhibiting protease | E. R. SQUIBB & SONS, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5760036-A | ENZYME INHIBITORS OF RETROVIRAL PROTEASE FOR PREVENTION OF AIDS | E. R. SQUIBB & SONS, INC. (US) | 1998-06-02 | — | — | US | disclosed |
| US-5559256-A | Aminediol protease inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0580402-A2 | Aminediol protease inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1994-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194768-A1 | PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION | HAVCR2, BRD7, ZC3HAV1 | SSTR4 4864/4885REN 4396/4885CTSC 845/4885 |
| US-20160326167-A1 | Novel Tetrahydropyridopyrimidines and Tetrahydropyridopyridines for the Treatment and Prophylaxis of Hepatitis B Virus Infection | TPMT, DPYD, HAVCR2 | SSTR4 3645/4885REN 679/4885CTSC 2760/4885 |
| US-11191775-B2 | PAPD5 and PAPD7 inhibitors for treating a hepatitis B infection | HAVCR2, BRD7, ZC3HAV1 | SSTR4 4864/4885REN 4396/4885CTSC 845/4885 |
| US-20220096527-A1 | PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION | HAVCR2, BRD7, BAZ2B | SSTR4 4865/4885REN 4044/4885CTSC 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.